Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
14
Not yet recruiting, industry sponsors, Oncology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed335
14 trials
Showing 1 to 14, recently updated first.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyDaiichi Sankyo (DSNKY)
NCT07949344 · 40 participants (planned) · Start Dec 1, 2026 · Primary completion Jun 30, 2030
Drug: Quizartinib; Chemotherapy · For: Acute Myeloid Leukemia
- CYTALUX Dose Extension StudyNot yet recruiting
On Target Laboratories, LLCIndustry
NCT07469202 · 106 participants (planned) · Start Nov 15, 2026 · Primary completion May 28, 2027
Drug: CYTALUX (pafolacianine) injection · For: Cancer in the Lung; Ovarian Cancer
PfizerPfizer (PFE)
NCT07881835 · 75 participants (planned) · Start Oct 22, 2026 · Primary completion Feb 16, 2029
Drug: Elranatamab · For: Relapsed/Refractory Multiple Myeloma; Multiple Myeloma
AstraZenecaAstraZeneca (AZN)
NCT07876817 · 50 participants (planned) · Start Oct 20, 2026 · Primary completion Jan 31, 2029
Drug: Durvalumab; Gemcitabine and 1 more · For: Muscle-Invasive Bladder Cancer (MIBC)
- A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in IndiaNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07822880 · 30 participants (planned) · Start Oct 2026 · Primary completion Oct 2029
Drug: Selpercatinib · For: Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung
Sites: Ahmedabad, India; Bengaluru, India; Bhubaneswar, India · 10 sites in all
- A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric CancerNot yet recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07829757 · 50 participants (planned) · Start Nov 30, 2026 · Primary completion Jul 31, 2029
Drug: Zolbetuximab; Oxaliplatin and 3 more · For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer and 1 more
- A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)Not yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07801027 · 150 participants (planned) · Start Nov 6, 2026 · Primary completion Jan 31, 2030
Drug: Pembrolizumab; Cisplatin and 4 more · For: Neoplasm Malignant; Gastric Neoplasms; Gastroesophageal Junction Adenocarcinoma and 2 more
- Tucatinib Continuation StudyNot yet recruiting
PfizerPfizer (PFE)
NCT07768358 · 175 participants (planned) · Start Nov 6, 2026 · Primary completion Mar 13, 2032
Drug: tucatinib · For: HER2-positive Breast Cancer; Cervical Cancer; Biliary Tract Neoplasms and 4 more
- A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07459543 · 40 participants (planned) · Start Nov 15, 2026 · Primary completion May 26, 2029
Drug: Nivolumab + Relatlimab · For: Unresectable Melanoma; Metastatic Melanoma
Sites: Nashik, India; Mumbai, India; Navi Mumbai, India · 11 sites in all
- A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial CancerNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07652515 · 100 participants (planned) · Start Aug 17, 2026 · Primary completion Aug 30, 2030
Drug: Dostarlimab; Carboplatin and 1 more · For: Neoplasms, Endometrial
- A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)Not yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT06897527 · 100 participants (planned) · Start Jul 15, 2025 · Primary completion Jan 13, 2027
Drug: Dostarlimab · For: Neoplasms, Endometrial
- A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian CancerNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT06887933 · 67 participants (planned) · Start Apr 22, 2025 · Primary completion Mar 20, 2026
Drug: Niraparib · For: Ovarian Neoplasms
SciClone PharmaceuticalsIndustry
NCT06047535 · 62 participants (planned) · Start Oct 31, 2023 · Primary completion Jun 15, 2027
Drug: Naxitamab · For: Neuroblastoma
- A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05367765 · 2,400 participants (planned) · Start Apr 30, 2022 · Primary completion Apr 30, 2027
Drug: Flumatinib; Imatinib · For: CML, Chronic Phase
Sites: Harbin, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.